Adalimumab
- Generic Name
- Adalimumab
- Brand Names
- Amjevita, Cyltezo, Humira, Hyrimoz, Yusimry, Hulio, Hefiya, Libmyris, Imraldi, Amsparity, Idacio, Hukyndra, Amgevita, Yuflyma
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 331731-18-1
- Unique Ingredient Identifier
- FYS6T7F842
- Background
Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor. It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA. This drug is frequently known as Humira. It is produced by recombinant DNA technology usi...
- Indication
Adalimumab is indicated for the following conditions:
Adalimumab has also been used off-label to treat Pyoderma gangrenosum.
- Associated Conditions
- Ankylosing Spondylitis (AS), Hidradenitis Suppurativa (HS), Moderate to Severe Chronic Plaque Psoriasis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Crohn's Disease, Moderately to Severely Active Ulcerative Colitis, Non-infectious Intermediate, Posterior and Panuveitis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Pyoderma Gangrenosum
- Associated Therapies
- -
Study of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19 (COMBAAT)
- First Posted Date
- 2021-01-12
- Last Posted Date
- 2022-03-03
- Lead Sponsor
- Resilience Government Services, Inc.
- Registration Number
- NCT04705844
A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2020-12-07
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT04655807
- Locations
- 🇺🇸
Medisphere Medical Research Center, Llc, Evansville, Indiana, United States
A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2021-06-23
- Lead Sponsor
- UCB Biopharma SRL
- Registration Number
- NCT04643483
Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- University of Erlangen-Nürnberg Medical School
- Target Recruit Count
- 270
- Registration Number
- NCT04610476
- Locations
- 🇩🇪
Universitätsklinikum Erlangen, Erlangen, Bavaria, Germany
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas
- Conditions
- Interventions
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2022-10-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT04551352
- Locations
- 🇧🇪
UZ Leuven Gasthuisberg, Leuven, Belgium
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2020-08-26
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 100
- Registration Number
- NCT04527380
- Locations
- 🇬🇧
Sheffield Children's Hospital, Sheffield, United Kingdom
🇬🇧Alder Hey Children's Hospital, Liverpool, England, United Kingdom
🇬🇧Oxford University Hospitals - Nuffield Orthopaedic Centre, Oxford, Oxfordshire, United Kingdom
Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Two Formulations of SB5 in Healthy Male Subjects
- First Posted Date
- 2020-08-17
- Last Posted Date
- 2021-05-26
- Lead Sponsor
- Samsung Bioepis Co., Ltd.
- Target Recruit Count
- 188
- Registration Number
- NCT04514796
- Locations
- 🇩🇪
Parexel International GmbH, Early Phase Clinical Unit Berlin, Berlin, Germany
Correlation of Serum Adalimumab Levels at an Administration of 40 mg Weekly vs 80 mg Every Two Weeks
- First Posted Date
- 2020-05-27
- Last Posted Date
- 2021-07-23
- Lead Sponsor
- Hospital Universitario La Paz
- Target Recruit Count
- 20
- Registration Number
- NCT04404517
- Locations
- 🇪🇸
Hospital Universitario La Paz, Madrid, Madrd, Spain
A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 455
- Registration Number
- NCT04230213
- Locations
- 🇨🇿
Lekarna Pod Platany, Praha, Czechia
🇧🇬Unimed Medical Centre, Plovdiv, Bulgaria
🇨🇿L.K.N. Arthrocentrum, s.r.o., Hlucin, Czechia
Adalimumab Dose Reduction Aiming Low Serum Concentration With Control of Disease Activity
- Conditions
- Interventions
- First Posted Date
- 2020-01-10
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Reade Rheumatology Research Institute
- Target Recruit Count
- 78
- Registration Number
- NCT04222920
- Locations
- 🇳🇱
Reade Rheumatology Research Institute, Amsterdam, Noord Holland, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.